ArticleScientific reports2026
Qualitative analysis of chemical components in Berberis kaschgarica Rupr. and study on the in vitro anti-inflammatory effects of its alkaloids.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Total Flavonoids fromAntioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Berberis kaschgarica Rupr. fruits (BKF) can reduce blood pressure, regulate blood lipid levels, and exert anti-inflammatory and anti-oxidative effects. Additionally, alkaloids are among the active components in BKF. Sensitive and selective high-performance liquid chromatography with mass spectrometry, network pharmacology, and bioinformatic analysis was conducted. We identified 544 metabolites and 105 secondary metabolites from BFK. Among the secondary metabolites, 24 were alkaloids. Moreover, there were 583 potential drug targets and 4,481 human anti-atherosclerosis targets. Finally, 366 intersecting targets of BFK against atherosclerosis were identified. These targets were enriched in 546 terms in biological processes, 48 terms in cell components, 121 terms in molecular functions, and 36 signaling pathways. Notably, 18 of the 24 alkaloids were fat-soluble alkaloids (FSA), and the remaining 6 were water-soluble alkaloids (WSA). Because oxyberberine (OBB) was predicted to have an ideal anti-atherosclerosis effect and was further studied. We established four intervention groups: FSA, WSA, total alkaloids (TA), and OBB. The effects of these alkaloids on caspase-11-induced pyroptosis and TLR4-induced inflammation in LPS-stimulated mouse macrophages in vitro were explored. The anti-pyroptosis results demonstrated significant evaluation in caspase-11, caspase-1, IL-1β, IL-18, and, GSDMD. Additionally, there were significant decreases in MMP3 and MMP9 in the supernatant, as well as the expression of TLR4 and pSTAT3. Conclusively, BKF contains numerous effective components, making it a valuable natural medicinal material with substantial developmental and utilitarian potential. In in vitro experiments, the alkaloids from BKF can reduce the LPS-induced expression of caspase-11 and GSDMD. Compared with previous studies on BKF, which had gaps in systematic identification of bioactive subtypes via basic colorimetry and unclear anti-AS mechanisms. our study advances research by using UPLC-MS/MS for the first time to identify 544 metabolitesin BKF, establishing a comprehensive metabolite profile and integrating network pharmacology and in vitro assays to first link BKF alkaloids to regulating caspase-11-mediated pyroptosis and TLR4-induced inflammation. Moreover, our findings contribute to compositional innovation, mechanistic breakthroughs, and translational value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.